Cargando…

Low Molecular Weight Heparin Treatment Patterns and Outcomes in Cancer Patients with Acute Venous Thromboembolism: A Nationwide Cohort Study in France

SIMPLE SUMMARY: Venous thromboembolism (VTE) is a common and often fatal complication in cancer patients. The initial treatment for VTE in cancer patients is typically low molecular weight heparins (LMWH), a type of anticoagulant that prevents VTE from recurring. However, information on outcomes of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bertoletti, Laurent, Gusto, Gaelle, Quignot, Nadia, Khachatryan, Artak, Chaves, Jose, Moniot, Audrey, Mokgokong, Ruth, Mahé, Isabelle
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10251904/ https://www.ncbi.nlm.nih.gov/pubmed/37296971 http://dx.doi.org/10.3390/cancers15113011

Ejemplares similares

Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France
por: Bertoletti, Laurent, et al.
Publicado: (2022)

Comparative Analysis of All-Cause Health Care Resource Utilization and Costs Among Venous Thrombosis Patients Without Cancer Prescribed Apixaban or VKAs in France
por: Mokgokong, Ruth, et al.
Publicado: (2022)

Survival and treatment patterns of patients with relapsed or refractory multiple myeloma in France — a cohort study using the French National Healthcare database (SNDS)
por: Touzeau, Cyrille, et al.
Publicado: (2021)

Editorial: Venous thromboembolism and pregnancy
por: Tardy, Bernard, et al.
Publicado: (2022)

Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?
por: Mahé, Isabelle, et al.
Publicado: (2015)

Safety of heparin prophylaxis for venous thromboembolism in patients with neurotrauma
por: Puri, G, et al.
Publicado: (2010)

Low-molecular-weight heparins in the treatment of venous thromboembolism
por: Ageno , Walter, et al.
Publicado: (2000)

Venous thromboembolism and COVID-19
por: Bertoletti, L., et al.
Publicado: (2020)

Immunothrombosis and the Role of Platelets in Venous Thromboembolic Diseases
por: Heestermans, Marco, et al.
Publicado: (2022)

Management of Cancer-Associated Thrombosis in France: A National Survey among Vascular Disease and Supportive Care Specialists
por: Mahé, Isabelle, et al.
Publicado: (2022)

Why differentiate low molecular weight heparins for venous thromboembolism?
por: Fareed, Jawed, et al.
Publicado: (2007)

Guidance for the practical management of the heparin anticoagulants in the treatment of venous thromboembolism
por: Smythe, Maureen A., et al.
Publicado: (2016)

Diagnostic Approach for Venous Thromboembolism in Cancer Patients
por: Helfer, Hélène, et al.
Publicado: (2023)

Colchicine as an adjunct to heparin for prophylaxis of venous thromboembolism in patients with COVID-19
por: Kow, Chia Siang, et al.
Publicado: (2021)

New orally active anticoagulant agents for the prevention and treatment of venous thromboembolism in cancer patients
por: Gerotziafas, Grigoris T, et al.
Publicado: (2014)

The use of fondaparinux for the treatment of venous thromboembolism in a patient with heparin-induced thombocytopenia and thrombosis caused by heparin flushes
por: Spyropoulos, Alex C, et al.
Publicado: (2008)

Spontaneous Heparin-Induced Thrombocytopenia and Venous Thromboembolism following Total Knee Arthroplasty
por: Baker, Kevin, et al.
Publicado: (2017)

Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives
por: Poenou, Geraldine, et al.
Publicado: (2022)

Unfractionated heparin or low-molecular-weight heparin for venous thromboembolism prophylaxis after hepatic resection: A meta-analysis
por: Zhang, Wentao, et al.
Publicado: (2022)

Adult breast, lung, pancreatic, upper and lower gastrointestinal cancer patients with hospitalized venous thromboembolism in the national French hospital discharge database
por: Couturaud, F., et al.
Publicado: (2023)

Coexistence of Antiphospholipid Syndrome and Heparin-Induced Thrombocytopenia in a Patient with Recurrent Venous Thromboembolism
por: Adediran, Samuel, et al.
Publicado: (2017)

Rivaroxaban versus Low-Molecular-Weight Heparin for Venous Thromboembolism in Gastrointestinal and Pancreatobiliary Cancer
por: Lee, Jang Ho, et al.
Publicado: (2019)

Effectiveness and Safety of Rivaroxaban and Low Molecular Weight Heparin in Cancer-Associated Venous Thromboembolism
por: Coleman, Craig I., et al.
Publicado: (2023)

Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis
por: Mai, Vicky, et al.
Publicado: (2019)

Incidence of Venous Thromboembolism: The 3(rd) Korean Nationwide Study
por: Hwang, Hun-Gyu, et al.
Publicado: (2022)

Venous thromboembolism and radiation therapy: The final radiation‐induced thrombosis study analysis
por: Daguenet, Elisabeth, et al.
Publicado: (2022)

Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events
por: Poénou, Géraldine, et al.
Publicado: (2023)

Cancer-Associated Venous Thromboembolism: A Practical Review Beyond Low-Molecular-Weight Heparins
por: Smrke, Alannah, et al.
Publicado: (2017)

Inhibition of Factor XI: A New Era in the Treatment of Venous Thromboembolism in Cancer Patients?
por: Poenou, Géraldine, et al.
Publicado: (2023)

Familial Clustering of Venous Thromboembolism – A Danish Nationwide Cohort Study
por: Sindet-Pedersen, Caroline, et al.
Publicado: (2016)

Estimate of Venous Thromboembolism and Related-Deaths Attributable to the Use of Combined Oral Contraceptives in France
por: Tricotel, Aurore, et al.
Publicado: (2014)

Prevention and treatment of venous thromboembolism with low-molecular-weight heparins: Clinical implications of the recent European guidelines
por: Prandoni, Paolo
Publicado: (2008)

Dealing with thrombocytopenia during anticoagulation with heparins for active venous thromboembolism: a play-it-safe practical approach
por: Abdel-Razeq, Hikmat, et al.
Publicado: (2011)

The economic impact of enoxaparin versus unfractionated heparin for prevention of venous thromboembolism in acute ischemic stroke patients
por: Pineo, Graham F, et al.
Publicado: (2012)

Prophylaxis of cancer-associated venous thromboembolism with low-molecular-weight heparin-tinzaparin: Real world evidence
por: Christopoulou, Athina, et al.
Publicado: (2022)

Methylprednisolone, venous thromboembolism, and association with heparin to 30 days in hospital survival in severe Covid-19 pneumonia
por: Go, Ronaldo C., et al.
Publicado: (2022)

Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study
por: Trujillo‐Santos, Javier, et al.
Publicado: (2022)

Family history of venous thromboembolism is a risk factor for venous thromboembolism in combined oral contraceptive users: a nationwide case-control study
por: Zöller, Bengt, et al.
Publicado: (2015)

Patient Characteristics and Preferences Regarding Anticoagulant Treatment in Venous Thromboembolic Disease
por: Lanéelle, Damien, et al.
Publicado: (2021)

Venous thromboembolism /
por: Hirsh, Jack, 1935-
Publicado: (1981)

Cannot write session to /tmp/vufind_sessions/sess_5tmr4nvsc6rq16sdujtots1634